Chronic pain, sleep disorders, neuropathy, and anxiety were the most common conditions that showed improvement in the study.
Here’s a brief look at therapies for neurological disorders that the FDA has approved within the past 6 months.
How much do you know about trigeminal neuralgia? Find out with this quick, 5-question quiz.
Over 10 million Americans suffer from debilitating chronic pain, according to new data that provides insights into the unrelenting problem of pain in America.
Results presented at the 2018 American Headache Society Annual Scientific Meeting suggested that 20% of participants achieved pain freedom two hours after a single dose of rimegepant, and 48% achieved pain freedom eight hours after that dose, compared to 12% and 32%, respectively, with placebo.
Research published more than 25 years ago was already reporting problems with opioid analgesics.
What are the key symptoms of TIND, a rare condition that can occur after rapid normalization of blood glucose levels following prolonged periods of hyperglycemia?
Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.
Some very recent research findings have added to the literature on the associations between migraine and depression, anxiety, and other disorders. Highlights here.